Short- and Midterm Results between Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Sleeve Gastrectomy for the Treatment of Morbid Obesity

Bandar Albeladi,Noel Huten,Céline Bourbao-Tournois

doi:10.1155/2013/934653

Abstract

Background. Laparoscopic Roux-en-Y gastric bypass (LRYGB) is one of the most widely used bariatric procedures today, and laparoscopic sleeve gastrectomy (LSG) as a single-stage procedure for the treatment of morbid obesity is becoming increasingly popular in Europe. The aim of this study was to compare short- and midterm results between LRYGB and LSG. Methods. An observational retrospective study from a database of patients undergoing LRYGB and LSG between January 2008 and June 2011. Seventy patients (mean age 39 years) were included. Patients were followed at 6, 12, and 18 months. Operative time, length of stay, weight loss, comorbidity improvement or resolution, postoperative complications, reinterventions and mortality were evaluated. Results. Thirty-six LRYGB and 34 LSG were included. Mean operative time of LSG was 106 min while LRYGB was 196 min (P < 0.001). Differences in length of stay, early and late complications, and improvement or resolution in comorbidities were not significant (P > 0.05). Eighteen months after surgery, average excess weight loss was 77.6% in LRYGB and 57.1% in LSG (P = 0.003). There was no surgery-related mortality. Conclusions. Both LRYGB and LSG are safe procedures that provide good results in weight loss and resolution of comorbidities at 18 months.

Highlights

The obesity epidemic continues to increase worldwide and is associated with many comorbidities resulting in increased mortality rates of obese people [1, 2].These comorbidities lead to a reduction in life expectancy, and in quality of life [3]
The long-term efficacy is under investigation and there are very few studies that compare it with other bariatric techniques, including Laparoscopic Roux-en-Y gastric bypass (LRYGB)
The satisfaction of the patients assessed by the medical team was 97% in the LRYGB group and 91% in the laparoscopic sleeve gastrectomy (LSG) group Table 3

Summary

Introduction

The obesity epidemic continues to increase worldwide and is associated with many comorbidities resulting in increased mortality rates of obese people [1, 2].These comorbidities lead to a reduction in life expectancy, and in quality of life [3]. The obesity epidemic continues to increase worldwide and is associated with many comorbidities resulting in increased mortality rates of obese people [1, 2]. Advocated Laparoscopic Roux-en-Y gastric bypass (LRYGB) is the most frequently performed bariatric procedure providing significant and sustained weight loss at long-term followup [6, 7]. Length of stay, weight loss, comorbidity improvement or resolution, postoperative complications, reinterventions and mortality were evaluated. Average excess weight loss was 77.6% in LRYGB and 57.1% in LSG (P = 0.003). Both LRYGB and LSG are safe procedures that provide good results in weight loss and resolution of comorbidities at 18 months

Objectives

Methods

Results